Yellowstone Biosciences

About Yellowstone Biosciences

Yellowstone Bio is a biotechnology company aiming to unlock a new class of therapeutically targetable frequently expressed antigens with the potential to significantly transform patient lives. Spun out of the University of Oxford, it focuses on pioneering research in cancer treatment, particularly acute myeloid leukemia (AML), and is headquartered in Oxford, UK.

Products & Services

Soluble Bispecific TCR-based Therapies:Therapeutic T-cell bispecific molecules targeting peptides presented by HLA-II, designed to selectively kill tumor cells while sparing healthy cells. Initially focused on AML, with potential applications in other cancers like ovarian, lung, colorectal, prostate, breast, renal, and melanoma.

Specialties

Cancer Therapeutics Acute Myeloid Leukemia (AML) Soluble Bispecific TCR-based Therapies HLA Class II Antigen Targeting Solid Tumor Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 20915000 MR: - FA: £16.5 million FAN: 20915000	D: 2024-06-20 FD: 2024-06-20	1 investors

Series A Latest

2024-06-20

$20.9M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paresh Vyas

Co-Founder and Chief Scientific Officer

J

James MacDonald

Chief Executive Officer

J

Julian Hirst

Co-Founder and Chief Financial Officer

I

Ita O'Kelly

Chief Operating Officer

G

Gonzalo Garcia

Interim Chief Business Officer

B

Ben Woolven

Launch Lead

View 8 more team members with Pro

Unlock Full Team Directory

Recent News